[


Journal

Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060

Informations de publication

Date de publication:
07 11 2023
Historique:
received: 07 06 2023
accepted: 17 07 2023
pmc-release: 07 11 2024
medline: 8 11 2023
pubmed: 26 9 2023
entrez: 25 9 2023
Statut: ppublish

Résumé

Translocator protein 18 kDa (TSPO) PET imaging is used to monitor glial activation. Recent studies have proposed TSPO PET as a marker of the epileptogenic zone (EZ) in drug-resistant focal epilepsy (DRFE). This study aims to assess the contributions of TSPO imaging using [ We compared [ The study included 23 patients. Visual analysis of [ [ Eudract 2017-003381-27. Inclusion of the first patient: September 24, 2018. This study provides Class IV evidence on the utility of [

Sections du résumé

BACKGROUND AND OBJECTIVES
Translocator protein 18 kDa (TSPO) PET imaging is used to monitor glial activation. Recent studies have proposed TSPO PET as a marker of the epileptogenic zone (EZ) in drug-resistant focal epilepsy (DRFE). This study aims to assess the contributions of TSPO imaging using [
METHODS
We compared [
RESULTS
The study included 23 patients. Visual analysis of [
DISCUSSION
[
TRIAL REGISTRATION INFORMATION
Eudract 2017-003381-27. Inclusion of the first patient: September 24, 2018.
CLASSIFICATION OF EVIDENCE
This study provides Class IV evidence on the utility of [

Identifiants

pubmed: 37748889
pii: WNL.0000000000207811
doi: 10.1212/WNL.0000000000207811
pmc: PMC10663012
doi:

Substances chimiques

N,N-diethyl-2-(2-(4-(2-fluoroethoxy)phenyl)-5,7-dimethylpyrazolo(1,5-a)pyrimidin-3-yl)acetamide 0
Fluorodeoxyglucose F18 0Z5B2CJX4D
TSPO protein, human 0
Receptors, GABA 0

Banques de données

EudraCT
['2017-003381-27']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1893-e1904

Informations de copyright

© 2023 American Academy of Neurology.

Références

Seizure. 2017 Jan;44:42-47
pubmed: 27884611
J Nucl Med. 2012 Feb;53(2):234-40
pubmed: 22238156
Epilepsia. 2019 Jun;60(6):1248-1254
pubmed: 31144767
Epilepsia. 2012 Aug;53(8):1333-40
pubmed: 22709127
J Cereb Blood Flow Metab. 1996 Sep;16(5):834-40
pubmed: 8784228
Eur J Nucl Med Mol Imaging. 2021 Dec;49(1):257-268
pubmed: 33779770
J Nucl Med. 2008 May;49(5):814-22
pubmed: 18413395
Epilepsia. 2009 Sep;50(9):2147-53
pubmed: 19389145
J Cereb Blood Flow Metab. 2012 Jan;32(1):1-5
pubmed: 22008728
J Cereb Blood Flow Metab. 2018 Feb;38(2):333-346
pubmed: 28178885
J Nucl Med. 2016 Dec;57(12):1927-1932
pubmed: 27339875
Epilepsia. 2000 Oct;41(10):1350-6
pubmed: 11051134
J Nucl Med. 2015 Jul;56(7):1048-54
pubmed: 26025960
Brain. 2016 Apr;139(Pt 4):1252-64
pubmed: 26984188
Hum Brain Mapp. 2003 Aug;19(4):224-47
pubmed: 12874777
Ann Neurol. 1992 Dec;32(6):789-94
pubmed: 1471870
Neurology. 2010 Dec 14;75(24):2168-75
pubmed: 21172840
Parkinsonism Relat Disord. 2021 Jan;82:29-36
pubmed: 33242662
J Neuroimaging. 2013 Jan;23(1):129-31
pubmed: 21223436
Epilepsia. 1998 Dec;39(12):1375-6
pubmed: 9860078
EJNMMI Res. 2012 Nov 08;2(1):60
pubmed: 23136853
JAMA Neurol. 2015 Aug;72(8):882-8
pubmed: 26052981
Radiology. 2021 Oct;301(1):166-177
pubmed: 34254858
Eur J Nucl Med Mol Imaging. 2021 Dec;49(1):221-233
pubmed: 34120191
Eur J Nucl Med Mol Imaging. 2021 Dec;49(1):146-163
pubmed: 33433698
Neurology. 1999 Dec 10;53(9):2199-203
pubmed: 10599809
J Nucl Med. 2015 May;56(5):701-6
pubmed: 25766898
Eur J Nucl Med Mol Imaging. 2021 Dec;49(1):246-256
pubmed: 33693967
Epilepsia. 2022 May;63(5):1238-1252
pubmed: 35166379
Brain. 2004 Jan;127(Pt 1):164-74
pubmed: 14534161
Nat Rev Neurol. 2019 Oct;15(10):594-606
pubmed: 31341275
Epilepsy Res Treat. 2012;2012:201651
pubmed: 22934162
Epilepsia. 2016 Sep;57(9):e191-4
pubmed: 27381590
Brain. 2018 Jun 1;141(6):1855-1870
pubmed: 29608645
J Nucl Med. 2009 Mar;50(3):468-76
pubmed: 19223401
Ann Neurol. 2020 Sep;88(3):477-488
pubmed: 32542728
N Engl J Med. 2011 Sep 8;365(10):919-26
pubmed: 21899452
J Neuroinflammation. 2021 Jan 6;18(1):8
pubmed: 33407581

Auteurs

Margaux Cheval (M)

From the Université Paris-Saclay (M.C., C.L., M.B., N.T.); BioMAPS (S.R., F.C., F.L.B.); Bicetre University Hospital (D.T., A.M.P.), Paris; and Imagerie Moléculaire In Vivo (V.B.), SHFJ, CEA, Orsay, France. margaux.cheval@aphp.fr.

Sebastian Rodrigo (S)

From the Université Paris-Saclay (M.C., C.L., M.B., N.T.); BioMAPS (S.R., F.C., F.L.B.); Bicetre University Hospital (D.T., A.M.P.), Paris; and Imagerie Moléculaire In Vivo (V.B.), SHFJ, CEA, Orsay, France.

Delphine Taussig (D)

From the Université Paris-Saclay (M.C., C.L., M.B., N.T.); BioMAPS (S.R., F.C., F.L.B.); Bicetre University Hospital (D.T., A.M.P.), Paris; and Imagerie Moléculaire In Vivo (V.B.), SHFJ, CEA, Orsay, France.

Fabien Caillé (F)

From the Université Paris-Saclay (M.C., C.L., M.B., N.T.); BioMAPS (S.R., F.C., F.L.B.); Bicetre University Hospital (D.T., A.M.P.), Paris; and Imagerie Moléculaire In Vivo (V.B.), SHFJ, CEA, Orsay, France.

Ana Maria Petrescu (AM)

From the Université Paris-Saclay (M.C., C.L., M.B., N.T.); BioMAPS (S.R., F.C., F.L.B.); Bicetre University Hospital (D.T., A.M.P.), Paris; and Imagerie Moléculaire In Vivo (V.B.), SHFJ, CEA, Orsay, France.

Michel Bottlaender (M)

From the Université Paris-Saclay (M.C., C.L., M.B., N.T.); BioMAPS (S.R., F.C., F.L.B.); Bicetre University Hospital (D.T., A.M.P.), Paris; and Imagerie Moléculaire In Vivo (V.B.), SHFJ, CEA, Orsay, France.

Nicolas Tournier (N)

From the Université Paris-Saclay (M.C., C.L., M.B., N.T.); BioMAPS (S.R., F.C., F.L.B.); Bicetre University Hospital (D.T., A.M.P.), Paris; and Imagerie Moléculaire In Vivo (V.B.), SHFJ, CEA, Orsay, France.

Florent L Besson (FL)

From the Université Paris-Saclay (M.C., C.L., M.B., N.T.); BioMAPS (S.R., F.C., F.L.B.); Bicetre University Hospital (D.T., A.M.P.), Paris; and Imagerie Moléculaire In Vivo (V.B.), SHFJ, CEA, Orsay, France.

Claire Leroy (C)

From the Université Paris-Saclay (M.C., C.L., M.B., N.T.); BioMAPS (S.R., F.C., F.L.B.); Bicetre University Hospital (D.T., A.M.P.), Paris; and Imagerie Moléculaire In Vivo (V.B.), SHFJ, CEA, Orsay, France.

Viviane Bouilleret (V)

From the Université Paris-Saclay (M.C., C.L., M.B., N.T.); BioMAPS (S.R., F.C., F.L.B.); Bicetre University Hospital (D.T., A.M.P.), Paris; and Imagerie Moléculaire In Vivo (V.B.), SHFJ, CEA, Orsay, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH